DOI and DOC

In a rarely seen legal battle unfolding in a DEA courtroom in Arlington, Virginia, the future of two key psychedelic research compounds, DOI and DOC, hangs in the balance. The DEA's move to classify the substances as Schedule I drugs has sparked fierce resistance from researchers, neuroscientists...

In a groundbreaking study published in Neuron, researchers at Johns Hopkins University uncovered how the psychedelic drug DOI (2,5-dimethoxy-4-iodoamphetamine) reduces anxiety by activating particular neurons in the brain. The research looks at a specific type of brain cell called parvalbumin-...

In a significant development for psychedelics research, a Drug Enforcement Administration (DEA) administrative law judge has rejected the agency's request to block key witnesses and evidence in an upcoming hearing. The case, set for November, challenges the DEA's proposed ban on two psychedelic...